The PI3K/AKT Pathway as a Target for Cancer Treatment

被引：635
|
作者：
Mayer, Ingrid A. [1 ,2 ,3 ]
Arteaga, Carlos L. [1 ,2 ,3 ]
机构：
[1] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, Breast Canc Program, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA
来源：
ANNUAL REVIEW OF MEDICINE, VOL 67 | 2016年 / 67卷
关键词：
phosphoinositide 3-kinase (PI3K)/AKT; mammalian target of rapamycin (mTOR); pathway inhibitors; breast cancer; lymphoproliferative disorders; mutation; CHRONIC LYMPHOCYTIC-LEUKEMIA; POSITIVE BREAST-CANCER; RENAL-CELL CARCINOMA; PIK3CA MUTATIONS; PHOSPHOINOSITIDE; 3-KINASE; PHOSPHATIDYLINOSITOL; ESTROGEN DEPRIVATION; TYROSINE KINASE; MAMMARY-TUMORS; UP-REGULATION;
D O I：
10.1146/annurev-med-062913-051343
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Anticancer targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Genes in the phosphoinositide 3-kinase (PI3K)/AKT pathway are the most frequently altered in human cancers. Aberrant activation of this pathway, as a result of these somatic alterations, is associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK are currently in clinical trials, alone or in combination, in both solid tumors and hematologic malignancies. These drugs are the focus of this review.
引用
收藏
页码：11 / 28
页数：18
相关论文
共 50 条
  • [21] The PI3K Pathway as a Therapeutic Target in Breast Cancer
    Ma, Cynthia X.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2015, 11 (03) : 23 - 29
  • [22] PI3K/AKT Pathway as a Potential Therapeutic Target In Myelodysplastic Syndrome
    Rezende, Denise C.
    Pacheco, Lorena Zaida
    Pelloso, Luis Arthur F.
    Chauffaille, Maria L.
    Silva, Marcal C. A.
    Kimura, Elisa
    Casaes-Rodrigues, Rafael L.
    Segreto, Helena
    Yamamoto, Mihoko
    Maranhao Bahia Kerbauy, Daniella Marcia
    BLOOD, 2010, 116 (21) : 780 - 780
  • [23] The PI3K/Akt pathway: a target for curcumin's therapeutic effects
    Aliyari, Mahdieh
    Ghoflchi, Sahar
    Hashemy, Seyed Isaac
    Hashemi, Seyedeh Fatemeh
    Reihani, Amirali
    Hosseini, Hossein
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2025, 24 (01)
  • [24] Inhibition of PI3K/AKT/mTOR pathway for the treatment of endometriosis
    Barra, Fabio
    Desideri, Lorenzo Ferro
    Ferrero, Simone
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (17) : 3626 - 3627
  • [25] The relation between PI3K/AKT signalling pathway and cancer
    Noorolyai, Saeed
    Shajari, Neda
    Baghbani, Elham
    Sadreddini, Sanam
    Baradaran, Behzad
    GENE, 2019, 698 : 120 - 128
  • [26] PI3K/AKT signaling pathway and cancer: an updated review
    Martini, Miriam
    De Santis, Maria Chiara
    Braccini, Laura
    Gulluni, Federico
    Hirsch, Emilio
    ANNALS OF MEDICINE, 2014, 46 (06) : 372 - 383
  • [27] Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
    Bryan T. Hennessy
    Debra L. Smith
    Prahlad T. Ram
    Yiling Lu
    Gordon B. Mills
    Nature Reviews Drug Discovery, 2005, 4 : 988 - 1004
  • [28] Obesity, the PI3K/Akt signal pathway and colon cancer
    Huang, X-F.
    Chen, J-Z.
    OBESITY REVIEWS, 2009, 10 (06) : 610 - 616
  • [29] Exploiting the PI3K/AKT pathway for cancer drug discovery
    Hennessy, BT
    Smith, DL
    Ram, PT
    Lu, YL
    Mills, GB
    NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (12) : 988 - 1004
  • [30] The Role of Curcumin in Cancer: A Focus on the PI3K/Akt Pathway
    Zoi, Vasiliki
    Kyritsis, Athanassios P.
    Galani, Vasiliki
    Lazari, Diamanto
    Sioka, Chrissa
    Voulgaris, Spyridon
    Alexiou, Georgios A.
    CANCERS, 2024, 16 (08)
12345